SanBio Co., Ltd.

SanBio Co., Ltd. develops, produces, and sells regenerative cell medicines for the central nervous system. Its lead candidate, SB623, has completed a phase 2 clinical trial for traumatic brain injury in the United States and Japan. The research pipeline also includes SB623 for chronic cerebral infarction, chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.